91 results on '"Goldman, M."'
Search Results
2. EARLY IMMUNOSUPPRESSION WEANING AFTER CADAVER LIVER TRANSPLANTATION USING ATG INDUCTION AND RAPAMYCIN
- Author
-
Donckier, V, primary, Buggenhout, A, additional, Troisi, R, additional, Lucidi, V, additional, Rogiers, X, additional, Nagy, N, additional, Craciun, L, additional, Bourgeois, N, additional, de Hemptinne, B, additional, and Goldman, M, additional
- Published
- 2008
- Full Text
- View/download PDF
3. A RANDOMIZED CONTROLLED TRIAL OF SHORT- VERSUS LONG-COURSE VANCOMYCIN AS A COMPONENT OF AN ANTIBIOTIC REGIMEN FOR FEBRILE NEUTROPENIC AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL (PBPC) TRANSPLANT RECIPIENTS.
- Author
-
Avery, R. K., primary, Pohlman, B., additional, Bolwell, B., additional, Tso, E., additional, Goormastic, M., additional, Adal, K. A., additional, Mendez, Z., additional, Goldman, M., additional, Mossad, S. B., additional, Kalaycio, M., additional, Capozzi, D., additional, Schmitt, S. K., additional, Andresen, S., additional, and Longworth, D. L., additional
- Published
- 2000
- Full Text
- View/download PDF
4. IN VITRO ANTIGEN PRESENTING CELL FUNCTION IS DEFICIENT IN STABLE LUNG TRANSPLANT RECIPIENTS.
- Author
-
Knoop, C., primary, Ismaili, J., additional, Bulté, F., additional, Abramowicz, D., additional, Goldman, M., additional, and Estenne, M., additional
- Published
- 1999
- Full Text
- View/download PDF
5. AN IL-5/EOSINOPHIL DEPENDENT PATHWAY PLAYS A CRUCIAL ROLE IN THE ACUTE REJECTION OF MHC CLASS-II INCOMPATIBLE SKIN GRAFTS.
- Author
-
Le Moine, A., primary, Surquin, M., additional, Demoor, F. X., additional, Flamand, V., additional, Pretolani, M., additional, Braun, M. Y., additional, Noël, J. C., additional, Goldman, M., additional, and Abramowicz, D., additional
- Published
- 1999
- Full Text
- View/download PDF
6. ACUTE SKIN GRAFT REJECTION INDUCED BY β2 MICROGLOBULIN- ASSOCIATED MINOR TRANSPLANTATION ANTIGENS: CHARACTERISATION IN β2 MICROGLOBULIN-DEFICIENT MICE.
- Author
-
Surquin, M., primary, Le Moine, A., additional, Demoor, F X., additional, Flamand, V., additional, Pretolani, M., additional, Goldman, M., additional, and Abramowicz, D., additional
- Published
- 1999
- Full Text
- View/download PDF
7. LUNG REJECTION OCCURS IN LUNG TRANSPLANT RECIPIENTS WITH BLOOD CHIMERISM1
- Author
-
Knoop, C., primary, Andrien, M., additional, Defleur, V., additional, Antoine, M., additional, de Francquen, P., additional, Goldman, M., additional, and Estenne, M., additional
- Published
- 1997
- Full Text
- View/download PDF
8. THE LONG-TERM EFFECTS OF PROPHYLACTIC OKT3 MONOCLONAL ANTIBODY IN CADAVER KIDNEY TRANSPLANTATION—A SINGLE-CENTER, PROSPECTIVE, RANDOMIZED STUDY
- Author
-
Abramowicz, D., primary, GOLDMAN, M., additional, PAUW, L. DE, additional, VANHERWEGHEM, J. L., additional, KINNAERT, P., additional, and VEREERSTRAETEN, P., additional
- Published
- 1992
- Full Text
- View/download PDF
9. Down-regulation of interleukin-2 and interferon-y, and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice
- Author
-
Wissing, K.M., Desalle, F., Abramowicz, D., Willems, F., Leo, O, Goldman, M., and Alegre, M.L.
- Published
- 1999
- Full Text
- View/download PDF
10. CD3 antibody-induced IL-10 in renal allograff recipients: An in vive and in vitro analysis
- Author
-
Herbelin, A., Abramowicz, D., de Groote, D., Naret, C., Kreis, H., Bach, J.F., Goldman, M., and Chatenoud, L.
- Published
- 1999
- Full Text
- View/download PDF
11. Chronic rejection of major histocompatibility complex class II-disparate skin grafts after anti-CD3 therapy: a model of antibody-independent transplant vasculopathy
- Author
-
Le Moine, A., Flamand, V., Noel, J.C., Fayt, I., Goldman, M., and Abramowicz, D.
- Published
- 1998
- Full Text
- View/download PDF
12. CLINICAL SIGNIFICANCE OF IN SITU DETECTION OF T LYMPHOCYTE SUBSETS AND MONOCYTE/MACROPHAGE LINEAGES IN HEART ALLOGRAFTS.
- Author
-
Hoshinaga, K., Mohanakumar, T., Goldman, M. H., Wolfgang, T. C., Szentpetery, S., Lee, H. M., and Lower, R. R.
- Published
- 1984
- Full Text
- View/download PDF
13. THE LONGTERM EFFECTS OF PROPHYLACTIC OKT3 MONOCLONAL ANTIBODY IN CADAVER KIDNEY TRANSPLANTATION—A SINGLECENTER PROSPECTIVE RANDOMIZED STUDY
- Author
-
Abramowicz, D., GOLDMAN, M., PAUW, L. DE, VANHERWEGHEM, J. L., KINNAERT, P., and VEREERSTRAETEN, P.
- Abstract
We conducted a randomized, prospective study to determine the long-term effects of prophylactic OKT3 in cadaveric renal transplantation. In the first group of patients (n=56) OKT3 (5 mg/day) was administered for the first 14 postoperative days in association with azathioprine (AZA) and low-dose steroids, cyclosporine (CsA) being introduced on day 11. The other group of patients (n=52) received CsA from the first POD, together with AZA and steroids. Both protocols were identical from POD 14 on. The total number of infections was higher in OKT3 patients (124/1455 patient-months [P-M] vs. 68/1320 in CsA patients, P<0.001) without impact on patient survival (94.5 in OKT3 vs. 93 in CsA patients). OKT3 patients experienced a lower number of rejection episodes (61 per 1455 P-M of risk exposure vs. 81/1320 in CsA patients, P<0.05). In addition, the frequency of corticoresistant rejection episodes was lower in OKT3 patients (9 out of 61 vs. 24 out of 81 in CsA patients, P<0.05). This resulted in a trend toward improved overall graft survival (83 vs. 75, P=0.12) and in a significant increase in immunological graft survival (92 vs. 79, P=0.02) in OKT3 patients at 3 years. Taken together, these data suggest that prophylactic OKT3 therapy might have long-term beneficial effects in cadaveric renal transplantation.
- Published
- 1992
14. Bacillary angiomatosis in a renal transplant recipient
- Author
-
Cline, M.S., Cummings, O.W., Goldman, M., Filo, R.S., and Pescovitz, M.D.
- Published
- 1999
- Full Text
- View/download PDF
15. Cyclosporine a Drives a Th17 and Th2 Mediated Post-Transplant Obliterative Airway Disease.
- Author
-
Lemaître, P., Vokaer, B., Charbonnier, L.-M., Iwakura, Y., Estenne, M., Goldman, M., Oberdan, L., Remmelink, M., and Le Moine, A.
- Published
- 2012
- Full Text
- View/download PDF
16. CROSS-PLATFORM BIOMARKER SIGNATURE TO IDENTIFY RENAL TRANSPLANT TOLERANCE IN HUMANS.
- Author
-
Perucha, E., Sagoo, P., Sawitzki, B., Tomiuk, S., Stephens, D. A., Brouard, S., Rebollo-Mesa, I., Hilton, R., Bourcier, K., Goldman, M., Wood, K. J., Newell, K., Warrens, A., Janssen, U., Volk, H., Soulillou, J., Lechler, R. I., and Hernandez-Fuentes, M. P.
- Published
- 2010
- Full Text
- View/download PDF
17. A RANDOMIZED CONTROLLED TRIAL OF SHORT VERSUS LONGCOURSE VANCOMYCIN AS A COMPONENT OF AN ANTIBIOTIC REGIMEN FOR FEBRILE NEUTROPENIC AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL PBPC TRANSPLANT RECIPIENTS.
- Author
-
Avery, R. K., Pohlman, B., Bolwell, B., Tso, E., Goormastic, M., Adal, K. A., Mendez, Z., Goldman, M., Mossad, S. B., Kalaycio, M., Capozzi, D., Schmitt, S. K., Andresen, S., and Longworth, D. L.
- Published
- 2000
18. IN VITROANTIGEN PRESENTING CELL FUNCTION IS DEFICIENT IN STABLE LUNG TRANSPLANT RECIPIENTS.
- Author
-
Knoop, C., Ismaili, J., Bulté, F., Abramowicz, D., Goldman, M., and Estenne, M.
- Published
- 1999
19. Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients.
- Author
-
Catalano C, Servais S, Bonvoisin C, Couturier B, Hildebrand M, Etienne I, Meuris C, Goffard JC, Wissing M, Goldman M, and Le Moine A
- Subjects
- Humans, Immunocompromised Host, SARS-CoV-2, COVID-19, Vaccines
- Abstract
Competing Interests: The authors declare no funding and conflicts of interest.
- Published
- 2021
- Full Text
- View/download PDF
20. Expansion of memory-type CD8+ T cells correlates with the failure of early immunosuppression withdrawal after cadaver liver transplantation using high-dose ATG induction and rapamycin.
- Author
-
Donckier V, Craciun L, Miqueu P, Troisi RI, Lucidi V, Rogiers X, Boon N, Degré D, Buggenhout A, Moreno C, Gustot T, Sainz-Barriga M, Bourgeois N, Colle I, Van Vlierberghe H, Amrani M, Remmelink M, Lemmers A, Roelen DL, Claas FH, Reinke P, Sawitzki B, Volk HD, Le Moine A, de Hemptinne B, and Goldman M
- Subjects
- Adult, Cadaver, Cytomegalovirus immunology, Graft Rejection immunology, Herpesvirus 4, Human immunology, Humans, Interleukin-7 blood, Isoantibodies blood, Lymphocyte Depletion, Antilymphocyte Serum administration & dosage, CD8-Positive T-Lymphocytes immunology, Immunologic Memory, Immunosuppression Therapy, Immunosuppressive Agents administration & dosage, Liver Transplantation, Sirolimus administration & dosage
- Abstract
Background: We report on a pilot study investigating the feasibility of early immunosuppression withdrawal after liver transplantation (LT) using antithymocyte globulin (ATG) induction and rapamycin., Methods: LT recipients received 3.75 mg/kg per day ATG from days 0 to 5 followed by rapamycin-based immunosuppression. In the absence of acute rejection (AR), rapamycin was withdrawn after month 4. Immunomonitoring included analysis of peripheral T-cell phenotypes and clonality, cytokine production in mixed lymphocyte reaction, and characterization of intragraft infiltrating cells., Results: Ten patients were enrolled between October 2009 and July 2010. In the first three patients, complete withdrawal of immunosuppression after month 4 led to AR. No further withdrawals of immunosuppressive were attempted. Two AR occurred in the remaining seven patients. ATG induced profound T-cell depletion followed by CD8(+) T-cell reexpansion exhibiting memory/effector-like phenotype associated with progressive oligoclonal T-cell expansion (Vβ/HPRT ratio) and gradually enhanced anti-cytomegalovirus and anti-Epstein-Barr virus T-cell frequencies. Patients developing AR were characterized by decreased TCAIM expression. AR were associated with increased donor-specific production of interferon (IFN)-γ and interleukin (IL)-17, increased intragraft expression of IFN-γ mRNA, and significant CD8(+) T-cell infiltrates colocalizing with IL-17(+) cells., Conclusion: High-dose ATG followed by short-term rapamycin treatment failed to promote early operational tolerance to LT. AR correlates with expansion of memory-type CD8(+) T cells and increased levels of IFN-γ and IL-17 in mixed lymphocyte reaction and in the graft. This suggests that resistance and preferential expansion of effector memory T-cell in lymphopenic environment could represent the major barrier for establishment of tolerance to LT in approaches using T-cell-depleting induction.
- Published
- 2013
- Full Text
- View/download PDF
21. Transplantation research: will we ever reach the holy grail?
- Author
-
Goldman M and Wood K
- Subjects
- Animals, Graft vs Host Disease prevention & control, Humans, Models, Animal, Transplantation Chimera, Graft Survival physiology, Research trends, Transplantation trends, Transplantation Tolerance physiology
- Published
- 2009
- Full Text
- View/download PDF
22. Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells.
- Author
-
Donckier V, Craciun L, Lucidi V, Buggenhout A, Troisi R, Rogiers X, Boon N, Gustot T, Moreno C, Bourgeois N, Colle I, Van Vlierberghe H, Nagy N, Praet M, Dernies T, Amrani M, Stordeur P, de Hemptinne B, and Goldman M
- Subjects
- Acute Disease, Biopsy, CD4-Positive T-Lymphocytes immunology, Cytokines genetics, Drug Administration Schedule, Graft Rejection pathology, Humans, Immune Tolerance drug effects, Immunosuppressive Agents administration & dosage, Interferon-gamma immunology, Liver Transplantation pathology, Lymphocyte Count, Lymphocyte Culture Test, Mixed, Pilot Projects, RNA, Messenger genetics, Sirolimus therapeutic use, CD8-Positive T-Lymphocytes immunology, Graft Rejection immunology, Immune Tolerance immunology, Immunosuppressive Agents therapeutic use, Interferon-gamma metabolism, Liver Transplantation immunology
- Abstract
We designed a pilot trial in cadaveric liver transplantation to determine whether induction with antithymocyte globulins (ATG) and sirolimus would allow immunosuppression withdrawal. Patients received ATG 3.75 mg/kg per day from day 1 to 5 after transplantation followed by sirolimus for 4 to 6 months. We monitored interleukin (IL)-7 serum levels, interferon (IFN)-gamma, and IL-2 mRNA accumulation in mixed leukocyte reaction and intragraft IFN-gamma mRNA expression. In the first three patients, immunosuppression discontinuation was followed by reversible acute rejection occurring on days 280, 246, and 163 posttransplantation, corresponding to days 140, 40, and 39 after drug withdrawal, respectively. At the time of rejection, blood CD8+ T-cells counts had returned to or above pretransplant levels in two of three patients, whereas CD4+ T-cell count remained low. IL-7 serum levels rose in all three patients in the first months after transplantation and IFN-gamma mRNA accumulated in mixed leukocyte reaction between recipient T cells and donor spleen cells at the time of rejection. High levels of IFN-gamma mRNA were consistently detected in liver biopsy performed at the time of rejection. In conclusion, lymphopenia-induced IL-7 production after induction with ATG and sirolimus might lead to emergence of IFN-gamma-secreting CD8+ T-cells responsible for acute rejection after immunosuppression withdrawal.
- Published
- 2009
- Full Text
- View/download PDF
23. The multiple facets of toll-like receptors in transplantation biology.
- Author
-
Alegre ML, Leemans J, Le Moine A, Florquin S, De Wilde V, Chong A, and Goldman M
- Subjects
- Animals, Antigen-Presenting Cells immunology, Epithelial Cells immunology, Graft Rejection immunology, Humans, Immunity, Cellular, Immunity, Innate, Lymphocytes immunology, Reperfusion Injury immunology, Signal Transduction immunology, Toll-Like Receptors metabolism, Transplantation Immunology, Transplantation Tolerance
- Abstract
Toll-like receptors (TLRs) belong to a family of pattern-recognition receptors for microbial products and endogenous molecules released by stressed cells. Experimental studies show that TLRs are involved in the process of acute allograft rejection and that their activation can prevent transplantation tolerance. Herein, we review the expression of TLRs and the impact of TLR signaling in different cell types in grafted organs including antigen-presenting cells, T and B lymphocytes, epithelial and endothelial cells. We then discuss the involvement of TLRs in the different phases of the rejection phenomenon and the impact of TLR-mediated events on regulatory circuits which dampen alloimmune responses.
- Published
- 2008
- Full Text
- View/download PDF
24. IL-17 production elicited by allo-major histocompatibility complex class II recognition depends on CD25posCD4pos T cells.
- Author
-
Benghiat FS, Craciun L, De Wilde V, Dernies T, Kubjak C, Lhomme F, Goldman M, and Le Moine A
- Subjects
- Animals, Bone Marrow Cells immunology, Bone Transplantation immunology, Cell Division immunology, Dendritic Cells transplantation, Forkhead Transcription Factors immunology, Isoantigens immunology, Lymphocyte Activation, Lymphocyte Culture Test, Mixed, Mice, Mice, Inbred C57BL, Transplantation, Homologous immunology, Transplantation, Isogeneic immunology, CD4-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Histocompatibility Antigens Class II immunology, Interleukin-17 biosynthesis, Interleukin-2 Receptor alpha Subunit immunology
- Abstract
Background: Interleukin (IL)-17 is involved in autoimmune inflammatory disorders and naturally occurring CD25pos regulatory T cells were shown to promote IL-17 synthesis. Because IL-17 is overproduced in certain types of allograft rejection, it is important to characterize the cells responsible for IL-17 synthesis and to define how IL-17 is regulated during alloimmune responses., Methods: Splenic CD4pos T cells were isolated from C57BL/6 mice and fractionated according to CD25 expression. T cells were stimulated by major histocompatibility complex class II-mismatched bone marrow-derived dendritic cells from bm12 mice, either immature or made mature by exposure to lipopolysaccharide. To track T cell populations, CD25negCD4pos and CD25posCD4pos were isolated from Thy1.1 and congenic Thy1.2 mice, respectively. Cell proliferation was quantified by CFSE dilution. IL-17-producing cells and FOXP3pos cells were enumerated by intracytoplasmic staining and cytokine levels in culture supernatants were measured by ELISA., Results: Addition of CD25posCD4pos T cells to CD25negCD4pos T cells inhibited IL-2, interferon-[gamma], and IL-13 production but promoted IL-17 synthesis on stimulation by allogenic immature DC. In this setting, IL-17 originated from CD25intCD4posFOXP3neg memory T cells, which depend on IL-2 to produce IL-17. Alloreactive CD25negCD4pos T cells were also induced to produce IL-17 when stimulated by mature DC in the presence of CD25highCD4posFOXP3pos T cells., Conclusions: We conclude that (1) the cellular source of IL-17 during an antiallo major histocompatibility complex class II response depends on the maturation status of allogenic DC, (2) whereas suppressing Th1 and Th2 cytokine synthesis, naturally occurring regulatory T cells, allow IL-17 production by alloreactive CD4pos T cells.
- Published
- 2008
- Full Text
- View/download PDF
25. Donor T-cell development in host thymus after heterotopic limb transplantation in mice.
- Author
-
Li Z, Benghiat FS, Kubjak C, Schuind F, Goldman M, and Le Moine A
- Subjects
- Animals, Bone Marrow Transplantation immunology, Cell Proliferation, Graft Rejection immunology, Homeodomain Proteins genetics, Homeodomain Proteins physiology, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, T-Lymphocytes immunology, Thy-1 Antigens metabolism, Thymus Gland immunology, Transplantation Chimera immunology, Extremities transplantation, T-Lymphocytes cytology, Thymus Gland cytology, Transplantation, Heterotopic immunology
- Abstract
We developed a mouse model of heterotopic limb transplantation in which we took advantage of Thy1.1 and Thy1.2 congenic strains to track and characterize donor T cells, to determine the role of recipient's thymus in mixed T-cell chimerism induction as well as transplant immunocompetence. The vascularized Thy1.1 limb graft composed of femur, muscle, and skin (VBT) survived long-term in more than 87.5% of Thy1.2 recipients. Percentages of donor-type Thy1.1 T cells increased from day 30 to 90 in thymus and spleen of recipients. Most peripheral donor T cells displayed a naïve phenotype and a few others were regulatory T cells. Thymectomy prevented peripheral T-cell chimerism. Congenic VBT in immunodeficient RAG mice restored their ability to reject skin allografts. These observations suggest that donor T cells differentiated in host thymus might contribute to maintenance of mixed chimerism after transplantation of tissue composite grafts that include vascularized bone.
- Published
- 2007
- Full Text
- View/download PDF
26. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
- Author
-
Kapessidou Y, Habran C, Buonocore S, Flamand V, Barvais L, Goldman M, and Braun MY
- Subjects
- Amino Acid Sequence, Animals, Female, Histocompatibility Antigens Class II analysis, Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Molecular Sequence Data, Receptors, Antigen, T-Cell physiology, Transplantation, Homologous, CD4-Positive T-Lymphocytes immunology, Endothelium, Vascular physiology, Graft Rejection immunology, Heart Transplantation immunology
- Abstract
Background: Whereas the participation of alloreactive T cells sensitized by indirect allorecognition in graft rejection is well documented, the nature of recipient antigen presenting cells recognized by indirect pathway CD4+ T cells within the graft has yet to be identified. The purpose of this study was to determine the role played by graft endothelium replacement in the immune recognition of cardiac allografts rejected by indirect pathway CD4+ T cells., Methods: Transgenic RAG2-/- mice expressing I-Ab-restricted male antigen H-Y-specific TcR were studied for their capacity to reject H-2k male cardiac allografts. Chronic vascular rejection in this model was due to the indirect recognition of H-Y antigen shed from H-2k male allograft and presented by the recipient's own I-Ab APC to transgenic T cells., Results: Immunohistochemical analysis of rejected grafts revealed the presence of numerous microvascular endothelial cells (EC) that expressed recipient's I-Ab MHC class II molecules. This observation suggested that graft endothelium replacement by I-Ab-positive cells of recipient origin could stimulate the rejection of male H-2k graft by I-Ab-restricted H-Y-specific T cells. To investigate further this possibility, hearts from H-2b-into-H-2k irradiation bone marrow (BM) chimera were transplanted in transgenic recipients. A direct correlation was observed between the presence of I-Ab-positive EC within myocardial microvessels and the induction of acute rejection of chimeric H-2k male cardiac allografts transplanted in transgenic recipients., Conclusions: We conclude that graft endothelium replacement by recipient-type cells is required for the rejection of cardiac allograft mediated by indirect pathway alloreactive CD4+ T cells.
- Published
- 2006
27. IL-4 deficiency prevents eosinophilic rejection and uncovers a role for neutrophils in the rejection of MHC class II disparate skin grafts.
- Author
-
Surquin M, Le Moine A, Flamand V, Rombaut K, Demoor FX, Salmon I, Goldman M, and Abramowicz D
- Subjects
- Animals, Female, Mice, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic immunology, Th1 Cells immunology, Th2 Cells immunology, Graft Rejection immunology, Histocompatibility Antigens Class II immunology, Interleukin-4 deficiency, Neutrophils physiology, Skin Transplantation immunology
- Abstract
Background: Acute rejection of MHC class II-disparate bm12 skin grafts by C57BL/6 recipient mice is characterized by massive graft infiltration by eosinophils, together with increased intragraft amounts of IL-4 and IL-5 mRNA. IL-5 blockade prevents the intragraft eosinophil infiltration and prolongs the survival of skin allografts. As the differentiation of T cell precursors into Th2 cells is largely driven by IL-4, we investigated the role of IL-4 in MHC class II-disparate allograft rejection., Methods: We performed skin grafts from MHC class II incompatible bm12 mice into wild-type C57BL/6 mice (IL-4) or C57BL/6 IL-4 deficient mice (IL-4). Graft survival, in vitro T cell reactivity, and histology were compared., Results: We observed that 50% of IL-4 mice rapidly rejected their bm12 allograft, whereas the other 50% retained their graft 60 days after transplantation. Histological examination of bm12 allografts retained by IL-4 mice showed a normal appearance with no inflammatory infiltrate and no eosinophils. Among IL-4 mice that acutely rejected their bm12 skin graft, we observed a dense polymorphonuclear infiltrate. The depletion of neutrophils significantly prolonged bm12 graft survival., Conclusions: Eosinophil infiltrates, typical of MHC class II disparate acute skin graft rejection, are critically dependent on the availability of IL-4. IL-4 mice reject MHC class II disparate skin grafts by a pathway of rejection where neutrophils play a direct causal role.
- Published
- 2005
- Full Text
- View/download PDF
28. Regulatory role of host CD8+ T lymphocytes in experimental graft-versus-host disease across a single major histocompatibility complex class II incompatibility.
- Author
-
de Lavareille A, Prigogine C, Paulart F, Nagy N, Habran C, Haddou NO, Le Moine A, Salmon I, Goldman M, and Flamand V
- Subjects
- Animals, CD4-Positive T-Lymphocytes pathology, CD8-Positive T-Lymphocytes pathology, Cell Proliferation, Eosinophilia pathology, Graft vs Host Disease metabolism, Graft vs Host Disease pathology, Immunoglobulin E biosynthesis, Interleukin-13 blood, Interleukin-5 blood, Isoantibodies biosynthesis, Mice, Mice, Inbred C57BL, Mice, Knockout, Th2 Cells immunology, beta 2-Microglobulin deficiency, Blood Group Incompatibility immunology, CD8-Positive T-Lymphocytes immunology, Graft vs Host Disease immunology, Histocompatibility Antigens Class II blood
- Abstract
Background: CD8+ T cells are known to regulate type 2 helper T cell (Th2) alloreactive immune responses but their mode of activation is unclear. We investigated the role of host CD8+ T cells in experimental Th2-type graft-versus-host disease (GVHD) where donor/recipient disparity is restricted to a single major histocompatibility complex (MHC) class II antigen., Methods: Immunoglobulin (Ig) E serum levels, eosinophilia and lymphoid tissue hyperplasia were compared after injection of bm12 CD4+ T cells in either wild-type or CD8+ T cell-deficient (CD8-/-) C57BL/6 mice. In vitro, we explored effects of the addition of CD8+ T cells from wild-type or IFN-gamma-/- mice in mixed leukocyte cultures prepared with beta2 microglobulin-deficient (beta2m-/-) CD4+ T cells as responders or beta2m dendritic cells as stimulators., Results: HyperIgE resolved after 3 weeks in wild-type hosts whereas it persisted for 6 weeks in CD8-/- hosts. Eosinophil infiltrates in lymph nodes were significantly enhanced in CD8-/- hosts. Increased serum levels of IL-5 and IL-13 in CD8-/- hosts confirmed the enhancement of Th2-type responses in the context of recipient CD8+ T cell deficiency. Hyperplasia of lymph nodes and spleen were similar in both groups, as well as in vivo proliferation of donor CD4+ T cells. In vitro, CD8+ T cell regulation of the alloreactive Th2 response depended on their production of IFN-gamma and did not require expression of beta2m on CD4+ T cells or antigen-presenting cells., Conclusions: Host CD8+ T cells regulate alloreactive Th2 responses during graft-versus-host disease through an IFN-gamma dependent pathway, independently of the recognition of beta2m-associated MHC class I molecules.
- Published
- 2005
- Full Text
- View/download PDF
29. A rapid test to monitor alloreactive responses in whole blood using real-time polymerase chain reaction.
- Author
-
Zhou L, Toungouz M, Donckier V, Andrien M, Troisi R, de Hemptinne B, Le Moine A, Dupont E, Goldman M, and Stordeur P
- Subjects
- Antibody Formation, CD3 Complex biosynthesis, Flow Cytometry, HLA-DR Antigens, Hematopoietic Stem Cells cytology, Histocompatibility Testing, Humans, Immunologic Techniques, Interferon-gamma metabolism, Interleukin-2 metabolism, Liver Transplantation, Lymphocyte Culture Test, Mixed, Peptides chemistry, RNA, Messenger metabolism, T-Lymphocytes immunology, Time Factors, Transplantation Chimera, Transplantation Tolerance, Cytokines biosynthesis, Leukocytes, Mononuclear cytology, Reverse Transcriptase Polymerase Chain Reaction methods, T-Lymphocytes cytology, Transplantation, Homologous methods
- Abstract
Rapid, simple, and reliable assays to monitor allogeneic responses are essential for the safe development of novel protocols of tailored immunosuppression. Herein, we describe a real-time polymerase chain reaction method based on interleukin-2 and interferon-gamma mRNA quantification upon stimulation of whole blood with allogeneic T cell-depleted peripheral blood mononuclear cells. The technique requires only small blood volumes and results can be obtained within 48 hours. Data obtained in a liver transplant patient receiving a tolerance induction protocol based on the infusion of donor-type hematopoietic stem cells suggest that this rapid whole blood mixed lymphocyte reaction assay could be valuable for the monitoring of patients undergoing solid organ or hematopoietic stem cell transplantation.
- Published
- 2005
- Full Text
- View/download PDF
30. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression.
- Author
-
Benghiat FS, Graca L, Braun MY, Detienne S, Moore F, Buonocore S, Flamand V, Waldmann H, Goldman M, and Le Moine A
- Subjects
- Animals, Cytokines immunology, Cytokines metabolism, Female, Graft Rejection immunology, Heart Transplantation immunology, Heart Transplantation pathology, Immunosuppression Therapy, Lymphocyte Culture Test, Mixed, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Rats, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell immunology, Receptors, Interleukin-2 metabolism, Skin Transplantation immunology, Skin Transplantation pathology, T-Lymphocytes metabolism, Th1 Cells immunology, Th1 Cells metabolism, Th2 Cells immunology, Th2 Cells metabolism, Transplantation, Transplantation, Homologous immunology, Graft Survival immunology, Receptors, Interleukin-2 immunology, T-Lymphocytes immunology
- Abstract
Background: Allografts are occasionally accepted in the absence of immunosuppression. Because naturally occurring CD4(+)CD25(+) regulatory T cells (natural CD25(+) Treg cells) have been shown to inhibit allograft rejection, we investigated their influence on the outcome of allografts in nonimmunosuppressed mouse recipients., Methods: We compared survival times of male CBA/Ca skin grafts in female CBA/Ca recipients expressing a transgenic anti-HY T-cell receptor on a RAG-1(+/+) (A1[M]RAG+) or a RAG-1(-/-) (A1[M]RAG-) background. Depletion of natural CD25(+) Treg cells in A1[M]RAG+ mice was achieved by in vivo administration of the PC61 monoclonal antibody. The influence of natural CD25(+) Treg cells on the fate of major histocompatibility complex class II-mismatched (C57BL/6X bm12)F1 skin or bm12 heart transplants in C57BL/6 recipients was also assessed. Finally, we investigated the impact of natural CD25(+) Treg cells on the production of T-helper (Th)1 and Th2 cytokines in mixed lymphocyte cultures between C57BL/6 CD4(+) CD25(-) T cells as responders and bm12 or (C57BL/6X bm12)F1 antigen-presenting cells as stimulators., Results: Male allografts were spontaneously accepted by female A1(M)RAG+ mice but readily rejected by female A1(M)RAG+ mice depleted of natural CD25(+) Treg cells by pretreatment with the PC61 monoclonal antibody. Depletion of CD25(+) Treg cells also enhanced eosinophil-determined rejection of (C57BL/6X bm12)F1 skin grafts or bm12 cardiac grafts in C57BL/6 recipients. Finally, natural CD25(+) Treg cells inhibited the production of interleukin (IL)-2, interferon-gamma, IL-5, and IL-13 in mixed lymphocyte culture in a dose-dependent manner., Conclusion: Natural CD25(+) Treg cells control Th1- and Th2-type allohelper T-cell responses and thereby influence the fate of allografts in nonimmunosuppressed recipients.
- Published
- 2005
- Full Text
- View/download PDF
31. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab.
- Author
-
Baudouin V, Crusiaux A, Haddad E, Schandene L, Goldman M, Loirat C, and Abramowicz D
- Subjects
- Antibodies, Monoclonal, Humanized, Basiliximab, Basophils immunology, Child, Preschool, Cross Reactions, Daclizumab, Enzyme-Linked Immunosorbent Assay, Humans, Immunization, Immunoglobulin G immunology, Immunoglobulin Idiotypes immunology, Male, Anaphylaxis etiology, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal immunology, Immunoglobulin E analysis, Immunosuppressive Agents adverse effects, Immunosuppressive Agents immunology, Receptors, Interleukin-2 immunology, Recombinant Fusion Proteins
- Abstract
Background: Repeated administration of chimeric or humanized monoclonal antibodies is generally well tolerated. Anti-idiotypic sensitization is rare and is considered to be of no clinical significance. We observed a child who experienced anaphylactic shock when he received a second course of basiliximab at the time of his second renal transplantation. We therefore searched for the presence of anti-basiliximab immunoglobulin (Ig) E in this patient., Methods: Serum levels of anti-basiliximab IgE, assay of the anti-murine reactivity of circulating anti-basiliximab IgE, and assays for serum anti-mouse antibodies and global anti-basiliximab anti-idiotypic antibodies were carried out by enzyme-linked immunosorbent assay. Anti-basiliximab IgE antibodies on circulating basophils were evaluated by the ability of the patient's blood to produce leukotrienes in vitro after exposure to basiliximab., Results: Sequential assays of serum samples by enzyme-linked immunosorbent assay indicated that anti-basiliximab IgE antibodies appeared after the second basiliximab course. There was no IgE reactivity toward a control murine IgG2a monoclonal antibody (mAb), indicating that the IgE response was directed exclusively against basiliximab idiotypes. There was no IgE reactivity against the humanized anti-interleukin-2 receptor mAb daclizumab, which was derived from a distinct parental murine mAb. Patient basophils harvested months after the anaphylactic shock produced leukotrienes in vitro on exposure to basiliximab., Conclusions: Patients exposed to chimeric antibodies may develop an anti-idiotypic IgE response that can trigger anaphylactic shock on further exposure. Specific anti-idiotypic IgE may be bound to basophils even in the absence of circulating IgE.
- Published
- 2003
- Full Text
- View/download PDF
32. Interleukin-9 promotes eosinophilic rejection of mouse heart allografts.
- Author
-
Poulin LF, Richard M, Le Moine A, Kiss R, McKenzie AN, Goldman M, Renauld JC, Van Snick J, and Braun MY
- Subjects
- Animals, Eosinophilia immunology, Interleukin-4 physiology, Interleukin-5 physiology, Interleukin-9 analysis, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Polymerase Chain Reaction, RNA, Messenger analysis, Th2 Cells immunology, Transplantation, Homologous, Eosinophils physiology, Graft Rejection physiopathology, Heart Transplantation, Interleukin-9 physiology
- Abstract
Background: Eosinophils participate in allograft rejection when donor-reactive helper T lymphocytes are T-helper type 2 (Th2)-biased. Whereas the involvement of interleukin (IL)-4 and IL-5 in these forms of rejection is well established, the role of IL-9, another Th2-type cytokine promoting eosinophilia, has not been determined., Methods: We first used real-time polymerase chain reaction to quantify IL-9 mRNA in rejected allografts in a mouse model of fully mismatched heart transplantation in which recipients were devoid of CD8 T cells and developed a Th2 alloimmune response. We then compared allograft survival in wild-type versus IL-9-deficient mice depleted of CD8 T cells. Finally, we compared the fate of major histocompatibility complex class II-mismatched cardiac transplants from wild-type versus IL-9 transgenic donors to determine the influence of IL-9 overexpression within the graft., Results: The Th2 alloimmune response in CD8-deficient mice was associated with the accumulation of IL-9 mRNA in the rejected graft. In IL-9-deficient recipients depleted of CD8 T cells, eosinophil infiltration of heart allografts did not develop, but rejection still occurred. In the major histocompatibility complex class II disparate model, heart allografts from IL-9 transgenic donors were acutely rejected, whereas grafts from wild-type donors did not develop rejection. Acute rejection of IL-9 transgenic hearts was associated with massive eosinophil infiltration and prevented by neutralization of either IL-4 or IL-5., Conclusion: IL-9 is critically involved in heart transplant eosinophilia in conjunction with IL-4 and IL-5.
- Published
- 2003
- Full Text
- View/download PDF
33. Infusion of donor-derived hematopoietic stem cells in organ transplantation: clinical data.
- Author
-
De Pauw L, Toungouz M, and Goldman M
- Subjects
- Antigens, CD34 metabolism, Bone Marrow Cells metabolism, Bone Marrow Transplantation, Cadaver, Graft Rejection epidemiology, Humans, Incidence, Kidney Transplantation, Transplantation Chimera, Hematopoietic Stem Cell Transplantation, Tissue Donors, Transplantation Conditioning methods, Transplantation Tolerance
- Abstract
Many strategies for tolerance induction have been developed, because this is the major goal of clinical transplantation. One of the most effective and best-studied approaches has been based on the injection of hematopoietic cells derived from the donor bone marrow, to establish a state of microchimerism in the recipient. A subset of hematopoietic stem cells might be responsible for the tolerogenic properties. These CD34+ bone marrow stem cells can be isolated and safely injected into kidney transplant recipients. In the authors' clinical trial, no adverse effects were observed, and the infusion of donor CD34+ cells was well tolerated.
- Published
- 2003
- Full Text
- View/download PDF
34. Tolerance induction in clinical transplantation: the pending questions.
- Author
-
Toungouz M, Donckier V, and Goldman M
- Subjects
- Dendritic Cells transplantation, Hematopoietic Stem Cell Transplantation, Humans, Stem Cell Transplantation, T-Lymphocytes transplantation, Transplantation Chimera, Transplantation Conditioning, Organ Transplantation, Transplantation Tolerance
- Abstract
Despite the dramatic improvement of early graft survival due to the introduction of cyclosporin, late graft loss caused by chronic rejection and the lethal consequences of long-term immunosuppression, such as infection and cancer, remain major concerns for the transplantation community. Tolerance induction would avoid these complications. The ways to go are controversial, reflecting the redundancy of rejection pathways. They include the induction of central tolerance by establishment of mixed chimerism through hematopoietic stem cell transplantation and the induction of "operational tolerance" through immunodeviation involving dendritic or regulatory T cells. Major advances have been made in animal models exploring these strategies and, some preliminary data are even now available in humans, allowing the initiation of pilot clinical trials. In this article, we discuss the key questions that these trials will have to address.
- Published
- 2003
- Full Text
- View/download PDF
35. Preconditioning of donors with interleukin-10 reduces hepatic ischemia-reperfusion injury after liver transplantation in pigs.
- Author
-
Donckier V, Loi P, Closset J, Nagy N, Quertinmont E, Le Moine O, Devière J, Goldman M, Gelin M, and Gianello P
- Subjects
- Alanine Transaminase blood, Animals, Graft Survival drug effects, Interleukin-10 blood, Swine, Tissue Donors, Interleukin-10 pharmacology, Ischemic Preconditioning, Liver Transplantation, Reperfusion Injury prevention & control
- Abstract
Background: Graft ischemia-reperfusion injury (IRI) resulting from postreperfusion inflammatory reaction remains a major cause of complications after liver transplantation. In this article, the authors investigated the effect of anti-inflammatory cytokine interleukin (IL)-10 on IRI, in a preclinical model of liver transplantation in pigs., Methods: Donor pigs received IL-10 or saline at the start of liver graft harvesting. After 5 hr of cold ischemia, liver grafts were transplanted into untreated recipient pigs. IRI severity was measured in recipients by transaminase release and by cellular infiltration and necrosis on liver biopsy specimens., Results: Donor IL-10 administration attenuated IRI, as indicated by significant reduction of mean peak of transaminase in recipients of grafts from IL-10-treated donors. In contrast, no significant differences in cell infiltration or amount of necrosis were observed on liver biopsy specimens between groups., Conclusions: Donor preconditioning with IL-10 may constitute an interesting pharmacologic approach to reduce IRI severity after liver transplantation.
- Published
- 2003
- Full Text
- View/download PDF
36. Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory t cells.
- Author
-
Vosters O, Nève J, De Wit D, Willems F, Goldman M, and Verhasselt V
- Subjects
- Cell Differentiation drug effects, Cell Differentiation immunology, Cells, Cultured, Flow Cytometry, Humans, Lipopolysaccharides pharmacology, Transplantation Immunology drug effects, Transplantation, Homologous, Acetylcysteine analogs & derivatives, Acetylcysteine pharmacology, Dendritic Cells cytology, Dendritic Cells drug effects, Immune Tolerance drug effects, Lysine analogs & derivatives, Lysine pharmacology, T-Lymphocytes cytology
- Abstract
Background: Drugs blocking dendritic cell (DC) maturation might be useful in transplantation by inhibiting the induction of primary alloimmune responses and promoting the emergence of regulatory T lymphocytes (Treg). We investigated the effects of Nacystelyn (NAL), an N-acetyl-L-cysteine derivative, on human DCs, paying attention to the T-cell responses elicited by NAL-treated DCs in vitro., Methods: Lipopolysaccharide (LPS) was used to induce the maturation of DCs naturally present in blood or generated from human monocytes cultured in interleukin-4 and granulocyte-macrophage colony-stimulating activity. We first analyzed the consequences of NAL on cytokine production and expression of major histocompatibility complex class II and costimulatory molecules. Monocyte-derived DCs were then used as stimulators in mixed leukocyte cultures with naive CD4 T cells. Cytokine levels were measured in culture supernatants; the phenotype of T cells and their capacity to inhibit the proliferation of third-party T-cell responders was determined at the end of the culture., Results: NAL proved to be a potent inhibitor of DC maturation in whole blood experiments and on monocyte-derived DCs. Alloreactive T cells stimulated with DCs pretreated with LPS in the presence of NAL produced much less interferon-gamma but similar levels of interleukin-13 compared with DCs treated with LPS alone. Immature DCs induced Treg, which was not observed with mature DCs. DCs cultured with LPS in the presence of NAL were as efficient as immature DCs to generate alloreactive T cells with regulatory activity., Conclusions: NAL is a potent inhibitor of DC maturation, which might be useful to promote allograft acceptance by inducing the differentiation of allospecific Treg.
- Published
- 2003
- Full Text
- View/download PDF
37. Bone marrow-derived immature dendritic cells prime in vivo alloreactive T cells for interleukin-4-dependent rejection of major histocompatibility complex class II antigen-disparate cardiac allograft.
- Author
-
Buonocore S, Flamand V, Goldman M, and Braun MY
- Subjects
- Animals, Bone Marrow Cells cytology, CD4-Positive T-Lymphocytes cytology, Cell Communication immunology, Cell Differentiation drug effects, Cell Differentiation immunology, Cells, Cultured, Chronic Disease, Dendritic Cells cytology, Dendritic Cells drug effects, Gene Expression immunology, Graft Survival immunology, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Histocompatibility Antigens Class II immunology, Immunophenotyping, Interferon-gamma genetics, Interleukin-4 genetics, Interleukin-5 genetics, Mice, Mice, Inbred C57BL, Transplantation, Homologous, Bone Marrow Cells immunology, CD4-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Graft Rejection immunology, Heart Transplantation immunology, Interleukin-4 immunology
- Abstract
Background: Dendritic cells (DC) at the immature state express low levels of major histocompatibility complex and costimulatory molecules and are poor stimulators of primary T-cell response in vitro. Injection of immature bone marrow-derived DC, however, was shown to prime in vivo alloreactive CD4 T lymphocytes toward type 2 cytokine-producing cells in the absence of CD8 T-cell activation., Methods: We undertook the present study to determine whether Th2-immunization by immature DC could lead to allograft rejection. We first analyzed, in the major histocompatibility complex class II antigen-disparate B6-anti-bm12 combination, the capacity of immature DC to regulate the activity of alloreactive CD4 T cells. We then determined, in this model of weak antigenicity, whether injection of bm12 DC in B6 recipients before transplantation could modify the survival of vascularized bm12 cardiac allografts., Results: We confirmed that in vitro immature DC are poor stimulators of T-cell alloresponse. However, when given in vivo, immature bm12 DC primed anti-bm12 T cells for the production of interleukin (IL)-4. Moreover, they induced the acute rejection of bm12 cardiac allograft. The process of rejection was dependent on IL-4 because immunization of IL-4-deficient mice did not trigger rejection., Conclusions: Allogeneic immature DC generated with granulocyte-macrophage colony-stimulating factor are potent stimulators of primary alloreactive response in vivo and prime for transplant rejection. Our results indicate that strategies based on immature DC for the induction of transplantation tolerance should be considered with caution.
- Published
- 2003
- Full Text
- View/download PDF
38. Increased production of interleukin-10 and interleukin-1 receptor antagonist after extracorporeal photochemotherapy in chronic graft-versus-host disease.
- Author
-
Craciun LI, Stordeur P, Schandené L, Duvillier H, Bron D, Lambermont M, Goldman M, and Dupont E
- Subjects
- Antibodies, Monoclonal pharmacology, Apoptosis, Chronic Disease, Coculture Techniques, Cytokines genetics, Graft vs Host Disease blood, Graft vs Host Disease physiopathology, Humans, Interleukin 1 Receptor Antagonist Protein, Interleukin-10 genetics, Interleukin-10 immunology, Interleukin-10 pharmacology, Lymphocytes physiology, Monocytes physiology, RNA, Messenger metabolism, Recombinant Proteins pharmacology, Sialoglycoproteins genetics, Graft vs Host Disease drug therapy, Interleukin-10 biosynthesis, Photopheresis, Sialoglycoproteins biosynthesis
- Abstract
Background: Mechanisms of action of extracorporeal photochemotherapy (ECP) in graft-versus-host disease are incompletely understood. It has been proposed that phagocytosis of apoptotic bodies by monocytes and macrophages induces their activation, a process that increases production of immunosuppressive cytokines. We analyzed apoptosis and cytokine secretion in an autologous coculture system combining peripheral blood lymphocytes (PBL) obtained after ex vivo ECP treatment and nonirradiated peripheral blood mononuclear cells (PBMC)., Methods: We studied 11 leukapheresis products treated by ECP from six patients with resistant limited or extensive chronic graft-versus-host disease. Purified PBL obtained by monocyte depletion of the buffy coat from leukapheresis products were mixed with nonirradiated PBMC. Nonirradiated PBL were used as control. Cytokine production was tested at the mRNA level by real-time reverse transcriptase-polymerase chain reaction for interleukin (IL)-10, IL-1 receptor antagonist (IL-1Ra), IL-1beta, tumor necrosis factor-alpha, and IL-12p40., Results: Morphologic analysis and flow cytometry displayed important lymphocyte apoptotic features culminating at 24 to 48 hr. Coculture of patient's PBMC with ultraviolet-irradiated PBL as compared with nonirradiated PBL resulted in significant increase of IL-10 mRNA (3418+/-1015 versus 10596+/-3402 mRNA copy numbers; P=0.001) and IL-1Ra mRNA (23890+/-6166 versus 41767+/-10181 mRNA copy numbers; P=0.001). Incubation with a neutralizing anti-IL-10 monoclonal antibody resulted in a marked decrease of IL-1Ra mRNA levels., Conclusion: Our findings are consistent with the fact that ECP modifies patient's autologous lymphocytes by inducing a process of apoptosis that activates monocytes and macrophages, leading to increased synthesis of IL-10 and IL-1Ra mRNAs. The induction of this latter mediator is dependent on IL-10.
- Published
- 2002
- Full Text
- View/download PDF
39. Multiple pathways to allograft rejection.
- Author
-
Le Moine A, Goldman M, and Abramowicz D
- Subjects
- Animals, Chemokines physiology, Humans, Immune System physiopathology, Isoantigens physiology, T-Lymphocytes physiology, Transplantation Immunology physiology, Transplantation, Homologous, Graft Rejection immunology
- Abstract
Allograft rejection results from a complex process involving both the innate and acquired immune systems. The innate immune system predominates in the early phase of the allogeneic response, during which chemokines and cell adhesion play essential roles, not only for leukocyte migration into the graft but also for facilitating dendritic and T-cell trafficking between lymph nodes and the transplant. This results in a specific and acquired alloimmune response mediated by T cells. Subsequently, T cells and cells from innate immune system function synergistically to reject the allograft through nonexclusive pathways, including contact-dependent T cell cytotoxicity, granulocyte activation by either Th1 or Th2 derived cytokines, NK cell activation, alloantibody production, and complement activation. Blockade of individual pathways generally does not prevent allograft rejection, and long-term allograft survival is achieved only after simultaneous blockade of several of them. In this review, we explore each of these pathways and discuss the experimental evidence highlighting their roles in allograft rejection.
- Published
- 2002
- Full Text
- View/download PDF
40. Dendritic cells transduced with viral interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo.
- Author
-
Buonocore S, Van Meirvenne S, Demoor FX, Paulart F, Thielemans K, Goldman M, and Flamand V
- Subjects
- Animals, Dendritic Cells immunology, Fas Ligand Protein, Humans, Dendritic Cells physiology, Interleukin-10 genetics, Membrane Glycoproteins genetics, Retroviridae genetics, Transduction, Genetic, Transplantation Tolerance
- Abstract
Dendritic cells (DC) are the most potent presenters of alloantigens and therefore are responsible for the induction of allograft rejection. Genetic modifications of DC allowing the expression of a tolerogenic molecule may render them immunosuppressive. We transduced bone marrow-derived DC with recombinant MFG retrovirus encoding either viral interleukin (vIL)-10 or Fas ligand (FasL) to induce transplantation tolerance. Up to 10 ng/ml of bioactive vIL-10 was produced by DC after transfer of the corresponding gene. Although the inhibitory properties of vIL-10-transduced DC were revealed in vitro in a mixed lymphocyte culture, no clear down-regulation of the allogeneic response was observed in vivo after single or multiple injections of those DC overexpressing vIL-10. When we transduced wild-type bone marrow-derived DC with recombinant MFG retrovirus encoding murine FasL, cells quickly died, probably because of suicidal or fratricidal Fas-dependent death. Indeed, only DC from Fas-deficient lpr mice survived to FasL gene transfer. Those FasL-transduced lpr DC exhibited a strong cytotoxic activity against Fas-positive targets in vitro. DC overexpressing FasL did not behave as immunosuppressive DC in vivo. The subcutaneous injection of FasL+ lpr DC in MHC class II-disparate mice hyperactivated the allospecific proliferation of T cells in the draining lymph nodes compared with mice treated with control-transduced DC. These results argue against the development of FasL+ DC or vIL-10-secreting DC as immunosuppressive tools in vivo. The alternative pathways of T-cell activation triggered by these genetically modified DC need to be investigated.
- Published
- 2002
- Full Text
- View/download PDF
41. Impaired antigen-presenting cell function contributes to T-cell hyporesponsiveness in stable lung transplant recipients.
- Author
-
Knoop C, Ismaili J, Bulté F, Abramowicz D, Estenne M, and Goldman M
- Subjects
- Cells, Cultured, HLA-DR Antigens analysis, Humans, Immunosuppressive Agents pharmacology, Interleukin-10 metabolism, Interleukin-12 deficiency, Isoantigens immunology, Monocytes immunology, Monocytes metabolism, Muromonab-CD3 pharmacology, T-Lymphocytes drug effects, T-Lymphocytes immunology, Tetanus Toxoid pharmacology, Antigen-Presenting Cells physiology, Lung Transplantation immunology, T-Lymphocytes physiology
- Abstract
Background: Peripheral blood mononuclear cells (PBMC) of stable renal or cardiac transplant recipients were previously shown to respond to allogeneic cells but not to soluble protein antigens. The aim of the present study was to assess the T-cell and antigen-presenting cell (APC) functions of stable lung transplant (LT) recipients., Methods: We obtained PBMC from 38 stable LT recipients. PBMC from healthy volunteers served as controls. PBMC were stimulated with either anti-CD3 monoclonal antibody, allogeneic PBMC, or tetanus toxoid (TT). T-cell activation was assessed by determination of interleukin (IL)-2 levels in culture supernatants; in some experiments, interferon-y levels were also determined. Patients' APC function was tested in a mixed leukocyte reaction using patients' PBMC as stimulators. The expression of class II MHC, B7.2, and CD40 molecules on patients' APC was determined by flow cytometry, and their production of IL-10 and IL-12 at the basal state and upon CD40 ligation was also measured., Results: Patients' T cells produced normal amounts of IL-2 in response to anti-CD3 monoclonal antibody and allogeneic PBMC. In contrast, the response of memory T cells to TT was severely blunted both in terms of IL-2 and interferon-y production. Patients' PBMC were poor stimulators in mixed leukocyte reaction, and class II MHC expression on patients' monocytes was significantly reduced. Patients' APC presented a modest but significant increase in basal IL-10 production and produced significantly less IL-12 upon CD40 ligation than control APC., Conclusions: T cells from stable LT recipients respond normally to stimuli that do not depend on autologous APC. The major impairment in the T-cell response to TT is caused by APC dysfunction, which involves decreased class II MHC expression and deficient IL-12 synthesis.
- Published
- 2000
- Full Text
- View/download PDF
42. Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice.
- Author
-
Wissing KM, Desalle F, Abramowicz D, Willems F, Leo O, Goldman M, and Alegre ML
- Subjects
- Animals, Antigen-Presenting Cells metabolism, CD3 Complex metabolism, Female, Graft Survival drug effects, Lymphocyte Count, Male, Mice, Mice, Inbred Strains, Skin Transplantation, Spleen cytology, T-Lymphocytes cytology, Antibodies, Monoclonal pharmacology, CD3 Complex immunology, Immunosuppressive Agents pharmacology, Interferon-gamma metabolism, Interleukin-10 biosynthesis, Interleukin-2 metabolism, Interleukin-4 biosynthesis
- Abstract
Background: Activating anti-CD3 monoclonal antibodies (mAbs), such as OKT3, are potent immunosuppressive agents that are widely used in clinical transplantation. We investigated whether the in vivo induction of T cell unresponsiveness contributes to the immunosuppressive properties of the anti-mouse-CD3 mAb 145-2C11., Methods: After a single in vivo administration of 145-2C11 residual T cells were restimulated in vivo and in vitro to assess cytokine production. Mice were also transplanted with allogeneic skin 9 days after 145-2C11 administration to investigate whether the immunosuppressive properties of the antibody persist after the reexpression of the T cell receptor., Results: Pretreatment with anti-CD3 mAbs caused a profound deficit in both interleukin- (IL) 2 and interferon- (IFN) y secretion upon restimulation in vivo, whereas IL-4 was only partially inhibited and IL-10 production was significantly increased. Purified T cells obtained from mice injected with anti-CD3 mAb also displayed deficient IL-2 and IFN-gamma production together with persisting IL-4 and IL-10 secretion. 145-2C11 had immunosuppressive properties that per sisted after the reexpression of the T cell receptor because mice transplanted with allogeneic skin 9 days after a single anti-CD3 mAb injection still had significantly prolonged graft survival (14.1+/-0.6 days vs. 10.7+/-0.4 days in controls, P<0.02). Blocking IL-4 and IL-10 by neutralizing mAbs further prolonged skin graft survival in mice injected with 145-2C11 (18.3+/-0.7 vs. 14.8+/-0.6 days, P<0.02)., Conclusion: The in vivo administration of the 145-2C11 anti-CD3 mAb results in the selective inhibition of Thl-type cytokine secretion upon restimulation, which correlates with a state of immunosuppression. The persistent production of Th2-type cytokines does not contribute to the anti-CD3 mAb-mediated prolonged survival of skin allografts in our experimental model.
- Published
- 1999
- Full Text
- View/download PDF
43. Inhibition of human dendritic cell functions by methylprednisolone.
- Author
-
Vanderheyde N, Verhasselt V, Goldman M, and Willems F
- Subjects
- Antigens metabolism, Antigens, CD biosynthesis, Antigens, Surface biosynthesis, B7-1 Antigen biosynthesis, B7-2 Antigen, Cell Survival drug effects, Dendritic Cells cytology, Endocytosis immunology, HLA-DR Antigens biosynthesis, Humans, Intercellular Adhesion Molecule-1 biosynthesis, Interleukin-12 metabolism, Isoantibodies immunology, Membrane Glycoproteins biosynthesis, T-Lymphocytes immunology, Tumor Necrosis Factor-alpha metabolism, Dendritic Cells drug effects, Dendritic Cells physiology, Methylprednisolone pharmacology
- Abstract
Background: The aim of this study was to better define how glucocorticoids influence primary human T cell responses. Dendritic cells (DC*) are the most effective antigen presenting cells able to activate naive T cells. Previous studies have shown that dexamethasone impaired the function of murine DC. Here, we analyzed how methylprednisolone (MP) might affect the function and maturation of human DC., Methods: Human DC were generated from peripheral blood mononuclear cells cultured in granulocyte macrophage-colony stimulating factor and interleukin (IL)4. DC maturation was induced either by lipopolysaccharide (LPS) or by fibroblast transfected with the CD40-ligand gene (3T6-CD40L). DC phenotype was characterized by flow cytometric analysis, their cytokine production by ELISA. The ability of DC to activate naive T cells was evaluated in mixed leukocyte reactivity., Results: Although MP did not affect viability of DC, it enhanced their antigen uptake and down-regulated their basal expression of CD86. The expression of CD80 and CD54 by DC was slightly decreased and HLA-DR expression was not modified. MP prevented LPS-induced DC maturation as assessed by the inhibition of CD86, CD80 and CD54 up-regulation, CD83 induction and production of TNF-alpha, IL-6, and IL-12. In contrast, when DC were stimulated by 3T6-CD40L, MP prevented only the synthesis of IL-12. Moreover, MP-treated DC were deficient in their ability to elicit proliferative responses of CD4+CD45RA+ allogeneic T cells as well as their synthesis of interferon (IFN)-gamma, IL-5, and IL-13. CONCLUSION. Glucocorticoids exert potent suppressive effects on human DC and thereby inhibit the induction of primary T cell responses.
- Published
- 1999
- Full Text
- View/download PDF
44. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
- Author
-
Wissing KM, Morelon E, Legendre C, De Pauw L, LeBeaut A, Grint P, Maniscalki M, Ickx B, Vereerstraeten P, Chatenoud L, Kreis H, Goldman M, and Abramowicz D
- Subjects
- Adult, Antibody Formation, Cytokines biosynthesis, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Fever prevention & control, Graft Survival immunology, Humans, Immunoglobulin M blood, Interferon-gamma biosynthesis, Interleukin-10 administration & dosage, Interleukin-10 blood, Interleukin-2 blood, Interleukin-8 blood, Male, Pilot Projects, Recombinant Proteins administration & dosage, Recombinant Proteins blood, Recombinant Proteins therapeutic use, Tumor Necrosis Factor-alpha biosynthesis, Immunosuppressive Agents adverse effects, Interleukin-10 therapeutic use, Kidney Transplantation immunology, Muromonab-CD3 adverse effects
- Abstract
Background: We conducted a randomized, double-blind, placebo-controlled, rising single-dose study to investigate the effects of recombinant human (rh) interleukin (IL) 10 in renal transplant patients who received OKT3 as induction therapy., Methods: Patients received 0.1 (n=6), 1 (n=6), or 10 microg/kg (n=3) rhIL-10 or placebo (n=6) intravenously 30 min before the first injection of 5 mg of OKT3. We monitored IL-10 serum levels, the effect of rhIL-10 on OKT3-induced cytokine production, clinical toxicity, and the incidence of immunization against OKT3., Results: Serum IL-10 levels in the three experimental groups reached 0.8+/-0.2, 7.9+/-1.3, and 118.6+/-7.3 ng/ml (mean+/-SEM), respectively, 30 min after rhIL-10 injection. Peak plasma levels of tumor necrosis factor-alpha (TNF-alpha) were reduced from 2953+/-1599 pg/ml in patients injected with OKT3 and placebo to 447+/-155, 703+/-246, and 459+/-246 pg/ml in patients injected with 0.1, 1, and 10 microg/kg rhIL-10, respectively. Values for 24-hr TNF-alpha area under the curve decreased from 8988+/-3551 pg x hr/ml in control patients to 2284+/-494, 3950+/-955, and 2420+/-931 pg x hr/ml for the 0.1, 1, and 10 microg/kg rhIL-10 dose groups, respectively (P=0.045). There was also a trend toward reduced plasma levels of IL-2, IL-8, and interferon-gamma in rhIL-10-pretreated patients. Although none of the patients who received placebo or 0.1 or 1 microg/kg rhIL-10 developed an IgM antibody response directed against OKT3 during the first 10 days, this occurred in all three patients who received the highest rhIL-10 dose. In two of these patients, neutralization of OKT3 was associated with a reversible acute rejection episode., Conclusions: Pretreatment with doses of up to 1 microg/kg rhIL-10 is safe and reduces the release of TNF-alpha induced by OKT3. However, higher doses might promote early sensitization to OKT3.
- Published
- 1997
- Full Text
- View/download PDF
45. Bilateral reduction mammoplasty in a patient treated with calcium channel blocker and cyclosporine after renal transplant: a case report.
- Author
-
Pan Y, Grindstaff A, Cassada D, Goldman M, and Taylor J
- Subjects
- Adult, Breast Diseases blood, Cadaver, Female, Humans, Male, Prolactin blood, Breast Diseases chemically induced, Breast Diseases surgery, Calcium Channel Blockers adverse effects, Cyclosporine adverse effects, Felodipine adverse effects, Immunosuppressive Agents adverse effects, Kidney Failure, Chronic surgery, Kidney Transplantation, Mammaplasty
- Abstract
A 28-year-old woman with end-stage renal disease secondary to diabetes mellitus and hypertension underwent cadaver renal transplant in April 1992. After surgery, she developed bilateral breast enlargement while she was taking cyclosporine for immunosuppression therapy and felodipine, a calcium channel blocker, for blood pressure control. She underwent bilateral reduction mammoplasty in June 1995 to treat progressive breast enlargement which interfered with her normal life activities. Through mechanisms only partially understood, calcium channel blockers and cyclosporine are reported to increase the serum prolactin level, producing gynecomastia in men. There is no report in current literature to support a similar phenomenon in women.
- Published
- 1997
- Full Text
- View/download PDF
46. Efficacy of rejection prophylaxis with OKT3.
- Author
-
Abramowicz D and Goldman M
- Subjects
- Adult, Cyclosporine therapeutic use, Humans, Kidney Transplantation immunology, Antibodies, Monoclonal therapeutic use, Graft Rejection prevention & control, Immunosuppressive Agents therapeutic use
- Published
- 1996
- Full Text
- View/download PDF
47. The IgE humoral response in OKT3-treated patients. Incidence and fine specificity.
- Author
-
Abramowicz D, Crusiaux A, Niaudet P, Kreis H, Chatenoud L, and Goldman M
- Subjects
- Animals, Antibodies, Antibodies, Anti-Idiotypic blood, Binding, Competitive, Epitopes, Humans, Immunoglobulin G blood, Immunosuppressive Agents blood, Immunosuppressive Agents immunology, Kinetics, Mice, Muromonab-CD3 blood, Muromonab-CD3 immunology, Immunoglobulin E biosynthesis, Immunosuppressive Agents therapeutic use, Muromonab-CD3 therapeutic use
- Abstract
We recently described a case of anaphylaxis occurring at the time of retreatment with OKT3 of a renal allograft recipient in whom, for the first time, high anti-OKT3 IgE levels were documented. This led us to examine a large series of sera from 181 OKT3-treated patients to better define the frequency of IgE sensitization, its fine specificity (anti-isotypic and/or anti-idiotypic) and its relation to the appearance of IgG anti-OKT3 antibodies (Abs). Six patients out of the 181 assayed have developed anti-OKT3 IgE Abs as detected by ELISA. The earliest time of appearance of IgE anti-OKT3 Abs was 10 days after starting OKT3 (range, 10-25). The IgE response peaked by day 18 (range, 11-35) and had usually disappeared at 3 months after treatment. A more careful dissection of the fine specificity of the IgE response revealed that three of the four patients tested had developed an exclusive anti-idiotypic response. In the last patient, an anti-isotypic component was present since anti-OKT3 IgE Abs also reacted with control IgG2a, IgG2b, and IgG3 monoclonal antibodies. Importantly, anti-OKT3 IgE Abs were only detected in heavily sensitized patients also showing high titers of IgG specific Abs by ELISA (> or = 1/1000) as well as "blocking" anti-OKT3 antibodies, as assessed by immunofluorescence. We conclude that (1) exposure to OKT3 may lead to specific IgE sensitization that, however, only appears in about 38% of the patients; (2) IgE Abs mostly appear in patients also showing high levels of conventional IgG anti-OKT3 Abs including the presence of "blocking" anti-idiotypic Abs, and (3) IgE Abs may be directed to both idiotypic and isotypic determinants of the monoclonal antibody.
- Published
- 1996
- Full Text
- View/download PDF
48. Influence of donor-recipient HLA-DR mismatches and OKT3 prophylaxis on cadaver kidney graft survival.
- Author
-
Vereerstraeten P, Dupont E, Andrien M, De Pauw L, Abramowicz D, Goldman M, and Kinnaert P
- Subjects
- Adult, Analysis of Variance, Cadaver, Drug Administration Schedule, Female, Follow-Up Studies, Graft Rejection immunology, Histocompatibility Testing, Humans, Male, Prospective Studies, Tissue Donors, Graft Rejection prevention & control, Graft Survival immunology, HLA-DR Antigens immunology, Kidney Transplantation immunology, Muromonab-CD3 therapeutic use
- Abstract
Previous studies from our center have shown that donor-recipient HLA-DR mismatches (MM), characterized by the presence of the DR antigen in the donor but not in the recipient or vice versa, are associated with differential effects on graft survival (GS): some of them are beneficial (BEN) with results similar to those of HLA-DR identical or compatible pairs (85% 18 months GS) and some are detrimental (DET) (64% 18 months GS), whereas the other MM, neither BEN nor DET (neutral [NEU]) yield intermediate results (78% 18 months GS). The aim of the present study was to update the results at a longer follow-up time and to assess whether they are influenced or not by prophylactic administration of anti-CD3 mAb (OKT3). The analysis of 234 transplantations performed from 1980 to 1994 with only 1 HLA-DR MM confirmed the BEN effects of HLA-DR5 in either the donor or the recipient and the DET effects of HLA-DR1 or -DR2 in the donor and of HLA-DR2 or -DRW6 in the recipient. These effects were independent of those exerted by other, HLA-DR not related, prognostic factors. The transplants with 1 HLA-DR MM were then compared with those with zero HLA-DR MM (n = 378) and 4 groups were formed according to 2 levels of HLA-DR MM (zero or BEN MM vs. NEU or DET MM) and immunosuppression (with vs. without OKT3 prophylaxis). GS at 5 years was 63% in the group with either zero or BEN MM as compared with 41% in the group with either NEU or DET MM in the absence of OKT3 prophylaxis (P < 0.02); in comparison, with OKT3 prophylaxis, GS at 5 years was 73% in the group with either zero or BEN MM as compared with 58% in the group with either NEU or DET MM (P = 0.07). We conclude that the differential effects of HLA-DR MM on GS are still observed under OKT3 prophylaxis, that the effects of HLA-DR and immunosuppression on graft outcome are additive, and that OKT3 induction therapy is superior to therapy without OKT3. These observations could have important implications for the allocation policy and management of renal transplants.
- Published
- 1995
- Full Text
- View/download PDF
49. Critical role of interleukin 4 in the induction of neonatal transplantation tolerance.
- Author
-
Donckier V, Wissing M, Bruyns C, Abramowicz D, Lybin M, Vanderhaeghen ML, and Goldman M
- Subjects
- Animals, Animals, Newborn, Antibodies, Monoclonal, Base Sequence, Cytokines biosynthesis, Interleukin-4 genetics, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Molecular Sequence Data, RNA, Messenger analysis, Interleukin-4 immunology, Lymph Nodes immunology, Tissue Transplantation
- Abstract
Neonatal injection of semiallogeneic cells is known to promote differentiation of donor-specific CD4+ T cells into TH2-like cells in the peripheral lymphoid organs. We reasoned that the propensity of neonatal T cells to synthesize high levels of IL-4 might be involved in this polarization of the alloreactive response and thereby in the development of neonatal transplantation tolerance. First, analysis of cytokine gene expression in lymph nodes after neonatal injection of 10(7) (A/J x BALB/c)F1 cells in BALB/c mice indicated that IL-4 but not IL-2 is rapidly produced by CD4+ cells after allogeneic challenge in vivo. To determine whether the early production of IL-4 was involved in the establishment of allotolerance, BALB/c mice neonatally injected with (A/J x BALB/c)F1 spleen cells received on days 1 and 3 after birth 1 mg of anti-IL-4 mAb (11B11) or the same amount of control mAb. When grafted with A/J skin at 4 weeks, 88% of mice treated with control mAb retained their graft for more than 50 days, whereas rejection occurred within 30 days in 93% of mice treated with anti-IL-4 mAb. Analysis of T cell functions after in vitro restimulation with A/J spleen cells indicated that early IL-4 neutralization did not prevent donor-specific CTL unresponsiveness but allowed the emergence of alloreactive T cells secreting increased levels of IL-2 and IFN-gamma. We conclude that early production of IL-4 is critical for the establishment of neonatal transplantation tolerance in this strain combination, which has disparities across the entire H-2 region.
- Published
- 1995
50. Detection of blood chimerism after lung and heart-lung transplantation. The superiority of nested as compared with standard polymerase chain reaction amplification.
- Author
-
Knoop C, Andrien M, Defleur V, Antonine M, de Francquen P, Goldman M, and Estenne M
- Subjects
- Adult, Alleles, Cell Movement, DNA analysis, DNA genetics, Exons, Female, HLA-DR Antigens genetics, HLA-DRB1 Chains, Humans, Male, Middle Aged, Polymerase Chain Reaction, Transplantation Chimera immunology, Heart-Lung Transplantation immunology, Leukocytes, Mononuclear cytology, Lung Transplantation immunology, Transplantation Chimera genetics
- Abstract
Migration of donor cells from the graft to various tissues of the recipient has been demonstrated after different types of solid organ transplants. Currently, the detection of donor cells in the recipient's tissues is most simply performed by polymerase chain reaction (PCR) amplification of a donor-specific gene. In the present study, we first determined in vitro the sensitivity of standard and nested PCR amplification with sequence-specific primers (PCR-SSP) of a donor-specific allele of the HLA-DRB1 gene and then used this technique to assess prospectively blood chimerism in two single-lung (SLT) and one heart-lung (HLT) transplant recipients. Standard PCR-SSP consisted in a single amplification round with sequence-specific primers for the donor-specific DRB1 allele. Nested PCR-SSP consisted in a first round of generic amplification of exon 2 of the DRB1 gene, followed by a second amplification round with primers specific for the donor allele. In vitro, nested PCR-SSP of the donor-specific allele was 1000-fold more sensitive than standard PCR-SSP and allowed the detection of 1 donor cell in 10(5) recipient cells. In vivo, standard PCR-SSP detected donor cells among the recipients' peripheral blood mononuclear cells (PBMCs) only during the first postoperative days, whereas nested PCR-SSP demonstrated their presence until the end of the first postoperative month in patients 1 and 2 and until 3 months after transplantation in patient 3. We conclude that donor cells can be detected in the peripheral blood of SLT and HLT recipients during the first postoperative months and that nested PCR-SSP amplification of a donor-specific HLA-DRB1 allele is much more sensitive than standard PCR-SSP to demonstrate such chimerism.
- Published
- 1994
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.